2023 Year In Review
For Investor Audiences
This page is intended for U.S. residents only

2023 Year in Review for Investor Audiences. This page is intended for U.S. residents only. 2023 Year in Review for Investor Audiences. This page is intended for U.S. residents only.

Regeneron’s co-Founders reflect on 2023 accomplishments.

JUMP TO OUR MISSION IN MOTION

Forging Our Future Through Scientific Innovation

2023 was another remarkable year of growth through scientific excellence. We brought two new medicines to people in need, advanced numerous possible first- and best-in-class opportunities in our pipeline and steadily grew our business.

We welcomed thousands of new colleagues to our offices around the globe and continued to work together with a science-first mindset to bring vital medicines to people with serious diseases.

DOWNLOAD OUR 2023 RESPONSIBILITY REPORT
DOWNLOAD OUR BETTER WORKPLACE. BETTER SCIENCE. BETTER WORLD. IMPACT REPORT

Dear Fellow Shareholders...

Regeneron, at its core, is a company dedicated to the discovery and development of innovative medicines manufactured and commercialized to the highest standards. This approach has established us as a world-class biotechnology company, making a true difference in people’s lives. Our ability to create game-changing technologies has disrupted the traditional drug discovery, development, and manufacturing processes, and allows us to continue to push the boundaries of science. Our success can be largely attributed to two factors: our talented team’s unwavering dedication to patients and our consistent strategy of investing and reinvesting in the highest quality science, research, and technologies.

Read the full company letter to shareholders in our 2024 Proxy Statement.

Regeneron 2024 Proxy Statement and Notice of Annual Shareholder Meeting. DOWNLOAD OUR 2024 PROXY STATEMENT
Headshot of President and Chief Executive Officer Leonard Schleifer.

Leonard S. Schleifer, MD, PhD

Board co-Chair, co-Founder, President and Chief Executive Officer

Leonard Schleifer's signature.
Headshot of President and Chief Scientific Officer George D. Yancopoulos.

George D. Yancopoulos, MD, PhD

Board co-Chair, co-Founder, President and Chief Scientific Officer

George Yancopoulos' signature.

Our Mission in Motion

Dive into Regeneron's journey, hearing straight from colleagues at the forefront of our scientific breakthroughs and responsible business approach.

Our focus on corporate responsibility
2:34
Our focus on genetic medicines
2:13
Our focus on cancer
2:16

Business Snapshot

KEY 2023 FINANCIAL HIGHLIGHTS

$13.1B

Total revenue

$4.4B

Total R&D investment

$2.2B

Total repurchased shares

Chart detailing Regeneron's year over year total revenue. Regeneron's revenue was $5.1 billion in 2018, $6.6 billion in 2019, $8.5 billion in 2020, $16.1 billion in 2021, $12.2 billion in 2022, and $13.1 billion in 2023. Chart detailing Regeneron's year over year total revenue. Regeneron's revenue was $5.1 billion in 2018, $6.6 billion in 2019, $8.5 billion in 2020, $16.1 billion in 2021, $12.2 billion in 2022, and $13.1 billion in 2023.